
European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
Published on January 6, 2025
scope of such potential regulatory approval; smaller than anticipated market opportunities for the Company’s products and product candidates
Other news
